Dupilumab, a monoclonal antibody that binds to IL-4Rα and blocks both IL-4 and IL-13 signaling pathways, induces a reduction in the pruritus score of patients with moderate to severe AD [51, 52]. Here, IL4 is linked to Alzheimer disease.